{"id":"placebo-of-darbepoetin-alfa","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of thromboembolic events"},{"rate":"null","effect":"Hypertension"},{"rate":"null","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Darbepoetin alfa works by binding to the erythropoietin receptor on the surface of red blood cell precursors, triggering a cascade of intracellular signaling events that ultimately lead to increased red blood cell production. This is particularly useful in patients with anemia associated with chronic kidney disease or cancer chemotherapy.","oneSentence":"Darbepoetin alfa is an erythropoiesis-stimulating protein that mimics the action of erythropoietin to stimulate red blood cell production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:13.837Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anemia associated with chronic kidney disease"},{"name":"Anemia associated with cancer chemotherapy"}]},"trialDetails":[{"nctId":"NCT03439137","phase":"PHASE3","title":"Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2018-02-14","conditions":"Anemia; Hemodialysis Dependent Chronic Kidney Disease","enrollment":323},{"nctId":"NCT01471015","phase":"PHASE1, PHASE2","title":"Darbe Administration in Newborns Undergoing Cooling for Encephalopathy","status":"COMPLETED","sponsor":"University of Utah","startDate":"2012-09","conditions":"Hypoxic Ischemic Encephalopathy","enrollment":30},{"nctId":"NCT02876835","phase":"PHASE3","title":"Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-09-27","conditions":"Anaemia","enrollment":3872},{"nctId":"NCT03071861","phase":"PHASE2","title":"Mild Encephalopathy in the Newborn Treated With Darbepoetin","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2017-12-01","conditions":"Neonatal Encephalopathy, Hypoxic-Ischemic Encephalopathy Mild","enrollment":28},{"nctId":"NCT03171818","phase":"PHASE2","title":"Darbepoetin for Ischemic Neonatal Stroke to Augment Regeneration","status":"UNKNOWN","sponsor":"UMC Utrecht","startDate":"2017-07-01","conditions":"PAIS, Neonatal Stroke, Perinatal Stroke","enrollment":80},{"nctId":"NCT01207778","phase":"","title":"Brain Imaging and Developmental Follow up of Infants Treated With Erythropoietin","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2010-03","conditions":"Prematurity","enrollment":77},{"nctId":"NCT00858364","phase":"PHASE3","title":"Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy","status":"TERMINATED","sponsor":"Amgen","startDate":"2009-07-17","conditions":"Non-Small Cell Lung Cancer, Anemia, Cancer","enrollment":2549},{"nctId":"NCT00436748","phase":"PHASE3","title":"Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease","status":"TERMINATED","sponsor":"Amgen","startDate":"2008-09-16","conditions":"Anemia, Chronic Kidney Disease, Kidney Disease","enrollment":116},{"nctId":"NCT00093015","phase":"PHASE3","title":"Trial to Reduce Cardiovascular Events With Aranesp® Therapy (TREAT)","status":"COMPLETED","sponsor":"Amgen","startDate":"2004-08-01","conditions":"Kidney Disease, Diabetes Mellitus, Anemia","enrollment":4038},{"nctId":"NCT00358215","phase":"PHASE3","title":"RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-06-01","conditions":"Heart Failure, Anemia, Cardiovascular Disease","enrollment":2278},{"nctId":"NCT01652872","phase":"PHASE3","title":"Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-07-30","conditions":"Anemia in Chronic Kidney Disease Patients Not on Dialysis","enrollment":756},{"nctId":"NCT02879305","phase":"PHASE3","title":"Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-09-28","conditions":"Anaemia, Aspergillosis, Allergic Bronchopulmonary","enrollment":2964},{"nctId":"NCT03543657","phase":"PHASE3","title":"Maintenance Treatment of Renal Anemia in Dialysis Subjects","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-06-23","conditions":"Anemia, Renal Insufficiency, Chronic","enrollment":229},{"nctId":"NCT02969655","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Daprodustat Compared to Darbepoetin Alfa in Japanese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-11-21","conditions":"Anaemia","enrollment":271},{"nctId":"NCT00334737","phase":"PHASE2","title":"Darbepoetin Administration to Preterm Infants","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2006-06","conditions":"Infant, Newborn","enrollment":102},{"nctId":"NCT03776032","phase":"PHASE3","title":"A Novel Erythropoiesis Stimulating Protein (NESP; Darbopoetin Alfa) for the Treatment of Anemia in Lung Cancer Patients Receiving Multi-cycle Platinum-Containing Chemotherapy","status":"COMPLETED","sponsor":"Amgen","startDate":"1999-09-14","conditions":"Anemia","enrollment":320},{"nctId":"NCT01977573","phase":"PHASE2","title":"A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-10-31","conditions":"Anaemia","enrollment":252},{"nctId":"NCT01362140","phase":"PHASE3","title":"Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)","status":"COMPLETED","sponsor":"Amgen","startDate":"2011-12-21","conditions":"MDS","enrollment":147},{"nctId":"NCT00086086","phase":"PHASE2","title":"Subcutaneous (SC) Darbepoetin Alfa in Subjects With Symptomatic Congestive Heart Failure (CHF) & Anemia","status":"COMPLETED","sponsor":"Amgen","startDate":"2003-08","conditions":"Congestive Heart Failure, Anemia","enrollment":150},{"nctId":"NCT01043991","phase":"PHASE3","title":"Intracoronary Injection of Epo After Myocardial Infarct \"Intra-CO-EpoMI\"","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2008-12","conditions":"Acute Myocardial Infarct","enrollment":54},{"nctId":"NCT00925587","phase":"PHASE3","title":"Evaluation of Monthly Darbepoetin Alfa Dosing for Correction of Anemia in Non-dialysis Chronic Kidney Disease","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-06","conditions":"Anemia, Chronic Kidney Disease","enrollment":358},{"nctId":"NCT00364845","phase":"PHASE3","title":"STIMULATE Study: Anemia Correction and Health-related Quality of Life (HRQoL) Outcomes in Elderly Chronic Kidney Disease (CKD) Patients","status":"TERMINATED","sponsor":"Amgen","startDate":"2006-09","conditions":"Anemia, Chronic Kidney Disease","enrollment":51},{"nctId":"NCT00091858","phase":"PHASE3","title":"Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2004-04","conditions":"Anemia, Cancer","enrollment":1000},{"nctId":"NCT00540384","phase":"PHASE1, PHASE2","title":"Dose-finding Study of Novel Erythropoiesis Stimulating Protein (NESP) for the Treatment of Anaemia in Subjects With Solid Tumours Receiving Multicycle Chemotherapy","status":"COMPLETED","sponsor":"Amgen","startDate":"1999-07","conditions":"Anemia, Solid Tumors","enrollment":405},{"nctId":"NCT00118638","phase":"PHASE3","title":"A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy","status":"COMPLETED","sponsor":"Amgen","startDate":"2004-03","conditions":"Anemia, Non-Myeloid Malignancies","enrollment":705},{"nctId":"NCT00344409","phase":"PHASE3","title":"A Double-blind Study of KRN321 for the Treatment of Anemia in Cancer Patients","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2006-03","conditions":"Anemia","enrollment":200},{"nctId":"NCT01363934","phase":"PHASE1","title":"To Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Erythropoietin","status":"COMPLETED","sponsor":"Green Cross Corporation","startDate":"2011-06","conditions":"Healthy Volunteer","enrollment":100},{"nctId":"NCT00375869","phase":"PHASE2","title":"Safety of Darbepoetin Alfa Treatment in Patients With Severe Traumatic Brain Injury","status":"COMPLETED","sponsor":"Royal Alexandra Hospital","startDate":"2006-11","conditions":"Traumatic Brain Injury","enrollment":10},{"nctId":"NCT00661999","phase":"PHASE3","title":"Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2006-01","conditions":"Anemia, Leukemia, Lymphoma","enrollment":502},{"nctId":"NCT00534456","phase":"PHASE3","title":"An Exploratory Sub-study for the RED-HF™ (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial","status":"TERMINATED","sponsor":"Amgen","startDate":"2007-01","conditions":"Anemia, Cardiovascular Disease, Congestive Heart Failure","enrollment":12},{"nctId":"NCT00110955","phase":"PHASE3","title":"Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy","status":"COMPLETED","sponsor":"Amgen","startDate":"2004-02","conditions":"Anemia, Non-Myeloid Malignancies","enrollment":391},{"nctId":"NCT00049985","phase":"PHASE2","title":"Heart Failure and Anemia","status":"COMPLETED","sponsor":"Amgen","startDate":"2002-07","conditions":"Heart Failure, Anemia","enrollment":300},{"nctId":"NCT00115167","phase":"PHASE3","title":"A Study of Darbepoetin Alfa in Anemic Subjects Not Receiving Chemotherapy Who Have Completed the 20010103 Study","status":"COMPLETED","sponsor":"Amgen","startDate":"2004-08","conditions":"Anemia, Cancer","enrollment":371},{"nctId":"NCT00095277","phase":"PHASE2","title":"Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects With Anemia of Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2004-10","conditions":"Anemia","enrollment":220},{"nctId":"NCT00119613","phase":"PHASE3","title":"A Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin Alfa","status":"COMPLETED","sponsor":"Amgen","startDate":"2002-12","conditions":"Small Cell Lung Cancer","enrollment":600}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":80,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo of Darbepoetin alfa","genericName":"Placebo of Darbepoetin alfa","companyName":"Bayer","companyId":"bayer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Darbepoetin alfa is an erythropoiesis-stimulating protein that mimics the action of erythropoietin to stimulate red blood cell production. Used for Anemia associated with chronic kidney disease, Anemia associated with cancer chemotherapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}